Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries

被引:185
作者
Waksman, Ron [1 ]
Erbel, Raimund [2 ]
Di Mario, Carlo [3 ]
Bartunek, Jozef [4 ]
de Bruyne, Bernard [4 ]
Eberli, Franz R. [5 ]
Erne, Paul [6 ]
Haude, Michael [2 ]
Horrigan, Mark [8 ]
Ilsley, Charles [3 ]
Boese, Dirk [2 ]
Bonnier, Hans [7 ]
Koolen, Jacques [7 ]
Luescher, Thomas F. [5 ]
Weissman, Neil J. [1 ]
机构
[1] Washington Hosp Ctr, Div Cardiol, Washington, DC 20010 USA
[2] W German Heart Ctr Essen, Dept Cardiol, Essen, Germany
[3] Royal Brompton & Harefield NHS Trust, London, England
[4] Ctr Cardiovasc, Dept Cardiol, Aalst, Belgium
[5] Univ Hosp, Div Cardiol, Zurich, Switzerland
[6] Kantonal Hosp, Dept Cardiol, Luzern, Switzerland
[7] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands
[8] Austin & Repatriat Med Ctr, Dept Cardiol, Melbourne, Vic, Australia
关键词
bioabsorbable magnesium stent; intravascular ultrasound; neointima; recoil; SIROLIMUS-ELUTING STENT; METAL STENTS; TRIAL; ANGIOPLASTY; MULTICENTER; RESTENOSIS; DISEASE; LESIONS;
D O I
10.1016/j.jcin.2008.09.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study aimed to evaluate the degradation rate and long-term vascular responses to the absorbable metal stent (AMS). Background The AMS demonstrated feasibility and safety at 4 months in human coronary arteries. Methods The PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting) was a prospective, multicenter clinical trial of 63 patients with coronary artery disease who underwent AMS implantation. Angiography and intravascular ultrasound (IVUS) were conducted immediately after AMS deployment and at 4 months. Eight patients who did not require repeat revascularization at 4 months underwent late angiographic and IVUS follow-up from 12 to 28 months. Results The AMS was well-expanded upon deployment without immediate recoil. The major contributors for restenosis as detected by IVUS at 4 months were: decrease of external elastic membrane volume (42%), extra-stent neointima (13%), and intra-stent neointima (45%). From 4 months to late follow-up, paired IVUS analysis demonstrated complete stent degradation with durability of the 4-month IVUS indexes. The neointima was reduced by 3.6 +/- 5.2 mm(3), with an increase in the stent cross sectional area of 0.5 +/- 1.0 mm(2) (p = NS). The median in-stent minimal lumen diameter was increased from 1.87 to 2.17 mm at long-term follow-up. The median angiographic late loss was reduced from 0.62 to 0.40 mm by quantitative coronary angiography from 4 months to late follow-up. Conclusions lntravascular ultrasound imaging supports the safety profile of AMS with degradation at 4 months and maintains durability of the results without any early or late adverse findings. Slower degradation is warranted to provide sufficient radial force to improve long-term patency rates of the AMS. (J Am Coll Cardiol Intv 2009;2:312-20) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:312 / 320
页数:9
相关论文
共 27 条
[1]   Quantitative assessment of of in-stent dimensions: A comparison of 64 and 16 detector multislice computed tomography to intravascular ultrasound [J].
Beohar, Nirat ;
Robbins, Joel D. ;
Cavanaugh, Brendan J. ;
Ansari, Asimul H. ;
Yaghmai, Vahid ;
Carr, James ;
Davidson, Charles J. .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2006, 68 (01) :8-10
[2]   Results of coronary stenting for restenosis [J].
Colombo, A ;
Ferraro, M ;
Itoh, A ;
Martini, G ;
Blengino, S ;
Finci, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (04) :830-836
[3]  
Di Mario Carlo, 2004, J Interv Cardiol, V17, P391, DOI 10.1111/j.1540-8183.2004.04081.x
[4]   Novel magnetic resonance-compatible coronary stent -: The absorbable magnesium-alloy stent [J].
Eggebrecht, H ;
Rodermann, J ;
Hunold, P ;
Schmermund, A ;
Böse, D ;
Haude, M ;
Erbel, R .
CIRCULATION, 2005, 112 (18) :E303-E304
[5]   Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:: a prospective, non-randomised multicentre trial [J].
Erbel, Raimund ;
Di Mario, Carlo ;
Bartunek, Jozef ;
Bonnier, Johann ;
de Bruyne, Bernard ;
Eberli, Franz R. ;
Erne, Paul ;
Haude, Michael ;
Heublein, Bernd ;
Horrigan, Mark ;
Ilsley, Charles ;
Boese, Dirk ;
Koolen, Jacques ;
Luescher, Thomas F. ;
Weissman, Neil ;
Waksman, Ron .
LANCET, 2007, 369 (9576) :1869-1875
[6]   Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents -: Three-year results of the RAVEL trial [J].
Fajadet, J ;
Morice, MC ;
Bode, C ;
Barragan, P ;
Serruys, PW ;
Wijns, W ;
Constantini, CR ;
Guermonprez, JL ;
Eltchaninoff, H ;
Blanchard, D ;
Bartorelli, A ;
Laarman, GJ ;
Perin, MA ;
Sousa, JE ;
Schuler, G ;
Molnar, F ;
Guagliumi, G ;
Colombo, A ;
Hayashi, EB ;
Wülfert, E .
CIRCULATION, 2005, 111 (08) :1040-1044
[7]   Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions [J].
Grube, E ;
Silber, S ;
Hauptmann, KE ;
Mueller, R ;
Buellesfeld, L ;
Gerckens, U ;
Russell, ME .
CIRCULATION, 2003, 107 (01) :38-42
[8]   Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? [J].
Heublein, B ;
Rohde, R ;
Kaese, V ;
Niemeyer, M ;
Hartung, W ;
Haverich, A .
HEART, 2003, 89 (06) :651-656
[9]   Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation [J].
Hofma, SH ;
van der Giessen, WJ ;
van Dalen, BM ;
Lemos, PA ;
McFadden, EP ;
Sianos, G ;
Ligthart, JMR ;
van Essen, D ;
de Feyter, PJ ;
Serruys, PW .
EUROPEAN HEART JOURNAL, 2006, 27 (02) :166-170
[10]   Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk [J].
Joner, Michael ;
Finn, Aloke V. ;
Farb, Andrew ;
Mont, Erik K. ;
Kolodgie, Frank D. ;
Ladich, Elena ;
Kutys, Robert ;
Skorija, Kristi ;
Gold, Herman K. ;
Virmani, Renu .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (01) :193-202